Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TACE + Lenvatinib + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Intra-arterial
01
Overview
This combination therapy regimen involves Transcatheter Arterial Chemoembolization (TACE) followed by the multi-kinase inhibitor Lenvatinib and a Programmed Cell Death Protein 1 (PD-1) inhibitor, such as Tislelizumab, Sintilimab, or Camrelizumab. It is being investigated by Sun Yat-sen University as a first-line treatment for unresectable hepatocellular carcinoma (HCC) presenting with spontaneous rupture, a potentially fatal complication with a poor prognosis. TACE is used to embolize tumor-feeding arteries and control bleeding while delivering localized chemotherapy (typically Lobaplatin and Pirarubicin). Lenvatinib provides anti-angiogenic and anti-proliferative effects by targeting multiple receptors, and the PD-1 inhibitor component aims to restore the anti-tumor immune response. This triple-modality approach is designed to provide both local and systemic control of the disease.
- Other names
- TACE + Lenvatinib + PD-1 Inhibitor for Ruptured HCCTACE + Lenvatinib + TislelizumabTACE + Lenvatinib + SintilimabTACE + Lenvatinib + Camrelizumab
02
Targets
DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on TACE + Lenvatinib + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TACE + Lenvatinib + PD-1 inhibitor.